Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neodolor
- Development stage
- Unknown
- Lead developer
- PharmaSGP
- Administration
- Oral
01
Overview
Neodolor is a homeopathic combination medicine developed and marketed by PharmaSGP for the treatment of headaches, including tension headaches, migraines, and nerve pain. It is formulated as a combination of five homeopathically potentiated active ingredients: Gelsemium sempervirens, Spigelia anthelmia, Iris versicolor, Cyclamen purpurascens, and Cimicifuga racemosa. Neodolor is available in tablet form and as an oral liquid (Neodolor LQ).
- Brand names
- NeodolorNeodolor LQ
- Other names
- Neodolor LQ flüssigNeodolor Tabletten
Beyond the preview
Go deeper on Neodolor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neodolor.